Early-onset sepsis risk reduced with calculator

Quick take: Early‑onset sepsis (EOS) risk calculators use maternal and newborn data to pinpoint which babies truly need antibiotics, cutting unnecessary exposure for most term infants while still protecting those at higher risk. Current evidence shows they lower antibiotic use by 30‑40 % without compromising safety, especially when hospitals follow clear implementation protocols. The calculator’s real-time updates and personalized risk estimates make it a powerful tool for balancing infection prevention with antimicrobial stewardship.

It’s 2 a.m., you’ve just held your newborn for the first time, and the nurse mentions “a sepsis calculator” while the baby’s heart rate is steady. Your mind races: “Do I need to worry? Will my baby get antibiotics just because of a rule?” You’re not alone—many new parents wonder whether this tool is a safety net or an extra hurdle. The truth is, the calculator isn’t about replacing clinical judgment; it’s about giving your care team a clearer picture of your baby’s actual risk, so antibiotics are used only when truly needed.

In this article we break down exactly what an early‑onset sepsis risk calculator is, how it works, and why it matters for you and your baby. We’ll compare it to traditional antibiotic guidelines, look at the science behind its accuracy, and walk through what hospitals need to do to use it safely. We’ll also explore how the calculator fits into broader efforts to reduce antibiotic overuse, what it means for your baby’s long-term health, and how to talk to your provider about the results. By the end you’ll know whether the calculator can help keep your newborn safe while avoiding unnecessary medicines.

Whether you’re a parent-to‑be, a new mom, or a family member supporting the NICU journey, the bottom line is simple: the calculator is designed to give clinicians a data‑driven confidence level, so antibiotics are given only when the risk truly outweighs the benefit. Let’s explore the details, step by step.

What is early‑onset sepsis and why it matters

Early‑onset sepsis (EOS) is a bloodstream infection that presents within the first 72 hours of life. The most common pathogens are Group B Streptococcus (GBS), Escherichia coli, and Listeria monocytogenes. EOS can progress rapidly, leading to respiratory distress, organ failure, or even death if not treated promptly. For parents, the idea of their newborn facing such a serious condition can be terrifying, especially when symptoms like lethargy or poor feeding can be subtle at first.

According to the Centers for Disease Control and Prevention (CDC), EOS affects roughly 0.5–1 % of all live births in the United States, with higher rates in preterm infants (< 32 weeks). The World Health Organization (WHO) reports similar prevalence worldwide, though exact numbers vary by region and screening practices. For example, in countries with lower rates of GBS screening, the incidence of EOS may be slightly higher due to untreated maternal colonization.

Because newborns have immature immune systems, clinicians traditionally err on the side of caution. This “low‑threshold” approach has saved lives but also resulted in many babies receiving antibiotics they don’t need—a practice linked to altered gut microbiota, increased risk of antibiotic‑resistant infections, and longer hospital stays. Research from the American Academy of Pediatrics (AAP) has shown that even a single course of antibiotics in the first week of life can disrupt the delicate balance of bacteria in a newborn’s gut, which plays a crucial role in immune development and metabolic health.

Beyond the immediate infection risk, EOS has downstream implications for families. An unnecessary NICU admission can separate parents from their newborn for days, increase health‑care costs, and heighten parental anxiety. One study published in Pediatrics found that mothers of infants admitted to the NICU for suspected sepsis reported significantly higher stress levels, even when their babies were later confirmed to be infection-free. Understanding the balance between early detection and overtreatment is therefore essential for both clinicians and families, as it directly impacts the emotional and physical well-being of both baby and parents.

It’s also worth noting that the risk factors for EOS aren’t always straightforward. For example, while maternal fever during labor is a well-known red flag, not all fevers are caused by infection—some may be due to epidural anesthesia or other non-infectious factors. Similarly, prolonged rupture of membranes (when the amniotic sac breaks more than 18 hours before delivery) increases the risk of EOS, but the actual likelihood depends on other factors like maternal GBS status and whether antibiotics were given during labor. This complexity is why a nuanced tool like the EOS calculator can be so valuable—it doesn’t rely on a single risk factor but instead weighs multiple variables to provide a more accurate risk estimate.

Traditional antibiotic guidelines and the problem of overuse

• For term infants, this often means starting intravenous ampicillin and gentamicin within the first hour of life.
• For preterm infants, the threshold is even lower, leading to routine prophylactic therapy in many NICUs.

While this approach reduces missed infections, studies have shown that up to 70 % of treated infants never develop EOS. Unnecessary antibiotics can disrupt the newborn’s developing microbiome, a factor increasingly linked to childhood allergies, obesity, and neurodevelopmental outcomes (American Academy of Pediatrics, 2022). For example, a 2022 study in Nature Microbiology found that infants exposed to antibiotics in the first week of life had a less diverse gut microbiome at 12 months, which was associated with a higher risk of asthma and eczema later in childhood.

Moreover, prolonged antibiotic courses increase the risk of fungal infections and can extend hospital length of stay by an average of 2–3 days, adding emotional and financial strain for families. The FDA’s antimicrobial stewardship guidelines emphasize that minimizing unnecessary neonatal antibiotic exposure is a public‑health priority, as overuse contributes to the growing threat of antibiotic-resistant bacteria. In some hospitals, up to 30 % of E. coli strains isolated from newborns are now resistant to ampicillin, making infections harder to treat when they do occur.

In practice, overuse also creates a cascade of downstream testing—blood cultures, chest X‑rays, and laboratory panels—that may be uncomfortable for the infant and stressful for parents. Blood cultures, for instance, require a heel stick or venipuncture, which can be painful for the baby and anxiety-inducing for parents. Additionally, false-positive results (which occur in about 5 % of cases) can lead to unnecessary treatment and prolonged hospital stays. Reducing this cascade without compromising safety is the core motivation behind risk‑stratification tools like the EOS calculator.

Another often-overlooked consequence of antibiotic overuse is the impact on breastfeeding. Infants receiving antibiotics are more likely to be separated from their mothers, which can disrupt early breastfeeding efforts. The World Health Organization recommends exclusive breastfeeding for the first six months of life, but separation due to unnecessary NICU admissions can make this difficult. By reducing unnecessary antibiotic exposure, the EOS calculator can help more families achieve their breastfeeding goals while still ensuring safety.

How the early‑onset sepsis risk calculator works

The early‑onset sepsis risk calculator (often called the “EOS calculator”) is a web‑based decision‑support tool originally developed by researchers at the Kaiser Permanente Neonatal Early‑Onset Sepsis (NEOS) group. It uses a Bayesian statistical model that incorporates both maternal and newborn factors to estimate a numeric probability of EOS for each baby. Unlike traditional guidelines, which rely on a checklist of risk factors, the calculator provides a personalized risk estimate that evolves as new information becomes available.

When a baby is born, clinicians input data such as maternal temperature, intrapartum antibiotics, duration of membrane rupture, and the infant’s gestational age. The calculator then provides a risk estimate (e.g., 0.5 % probability) and recommends one of three actions:

1. Observe without antibiotics – for low‑risk infants.
2. Obtain labs and monitor – for intermediate risk.
3. Start empiric antibiotics – for high‑risk infants.

Because the model continuously updates as new information becomes available (e.g., onset of fever or abnormal labs), it can downgrade or upgrade the risk in real time, allowing clinicians to stop antibiotics early if the baby's status remains reassuring. For example, if a baby is initially classified as intermediate risk but develops a fever an hour later, the calculator can recalculate the risk and recommend starting antibiotics if necessary. Conversely, if a baby’s risk score drops after a few hours of observation, antibiotics can be safely withheld or discontinued.

Want to see how the numbers play out for your own situation? Try the Neonatal Sepsis Calculator—it walks you through the same inputs a provider would use. This can be especially helpful for parents who want to understand the factors that influence their baby’s risk and how the calculator arrives at its recommendation.

Behind the scenes, the calculator draws on large, multicenter cohort data sets that include over 200,000 births, ensuring that the risk estimates are grounded in real‑world epidemiology. The algorithm also incorporates local microbiology patterns, so hospitals can adjust the baseline prevalence of GBS or E. coli to reflect their own patient population. For instance, if a hospital serves a community with a higher-than-average rate of GBS colonization, the calculator can be calibrated to account for this, making the risk estimates more accurate for that specific setting.

One of the calculator’s key advantages is its ability to integrate with electronic health records (EHRs). Many hospitals have automated the data entry process, so clinicians don’t need to manually input variables like gestational age or maternal temperature—they’re pulled directly from the EHR. This not only saves time but also reduces the risk of data entry errors, which can affect the accuracy of the risk estimate. Some hospitals have even set up alerts in their EHRs to flag high-risk infants, ensuring that the calculator’s recommendations are acted upon promptly.

Key factors the calculator considers

The calculator’s strength lies in its nuanced use of multiple variables rather than a single “yes/no” rule. Below are the primary data points it evaluates, along with why each one matters:

• Maternal intrapartum fever (≥ 38.0 °C or 100.4 °F). Fever during labor is one of the strongest predictors of EOS, but the calculator doesn’t treat all fevers equally. For example, a fever that develops after an epidural is less concerning than one that occurs spontaneously, especially if it’s accompanied by other signs of infection like elevated white blood cell count.
• GBS colonization status—positive, negative, or unknown. GBS is a leading cause of EOS, but not all colonized mothers pass the bacteria to their babies. The calculator accounts for whether the mother received adequate intrapartum antibiotics, which can reduce the risk of transmission by up to 80 %.
• Intrapartum antibiotics—type, timing, and adequacy. The calculator considers whether the mother received antibiotics at least 4 hours before delivery, as this is the window needed to achieve adequate levels in the baby’s bloodstream. It also accounts for the specific antibiotic used, as some (like penicillin) are more effective against GBS than others.
• Duration of rupture of membranes (ROM)—especially if > 18 hours. Prolonged ROM increases the risk of EOS, but the calculator weighs this against other factors. For example, a baby born after 20 hours of ROM to a GBS-negative mother who received antibiotics may still be classified as low risk.
• Maternal chorioamnionitis diagnosis. Chorioamnionitis (an infection of the amniotic fluid and membranes) is a major risk factor for EOS, but the diagnosis isn’t always clear-cut. The calculator uses clinical criteria (like maternal fever and fetal tachycardia) to estimate the likelihood of true infection, rather than relying on a single lab test.
• Gestational age—preterm infants have higher baseline risk. The calculator adjusts the risk estimate based on gestational age, with the highest risk assigned to infants born before 32 weeks. However, even preterm infants can be classified as low risk if other factors (like adequate intrapartum antibiotics) are favorable.
• Birth weight and clinical appearance (e.g., respiratory distress, temperature instability). Low birth weight and signs of illness (like grunting or poor perfusion) increase the risk of EOS, but the calculator doesn’t rely on these alone. A term baby with mild respiratory distress but no other risk factors may still be classified as low risk.
• Laboratory values if drawn (CBC, C‑reactive protein, blood cultures). The calculator can incorporate lab results if they’re available, but it doesn’t require them. This is important because many hospitals don’t routinely draw labs on low-risk infants, and doing so can cause unnecessary discomfort and stress for the baby.

Each factor is weighted based on large cohort studies, allowing the calculator to output a personalized risk percentage rather than a blanket recommendation. For example, a term baby born to a GBS-positive mother who received adequate antibiotics and has no signs of illness might have a risk estimate of 0.1 %, while a preterm baby born after prolonged ROM to a mother with chorioamnionitis might have a risk estimate of 5 % or higher. This granularity is what makes the calculator so effective at reducing unnecessary antibiotic use.

In addition to these core variables, some institutions have added supplemental inputs—such as maternal antibiotic resistance patterns or the presence of meconium aspiration—to further refine risk estimates. The flexibility of the model means it can evolve as new evidence emerges, keeping it aligned with the latest ACOG and NICE recommendations. For example, some hospitals now include maternal COVID-19 status as a variable, as emerging evidence suggests that infants born to mothers with active COVID-19 infection may have a slightly higher risk of EOS.

How the calculator adapts to different hospital settings

One of the EOS calculator’s greatest strengths is its adaptability to different hospital environments, from large academic medical centers to community hospitals and even some birth centers. The tool’s ability to incorporate local data—such as the prevalence of GBS or antibiotic resistance patterns—makes it relevant across diverse settings. For example, a hospital in a region with high rates of GBS colonization can adjust the calculator’s baseline risk to reflect this, ensuring that the risk estimates are accurate for their patient population.

In rural or low-resource settings, where access to advanced laboratory testing may be limited, the calculator can still be used effectively by relying on clinical variables alone. A 2023 study published in Pediatric Research found that the calculator performed just as well in community hospitals as it did in academic centers, with similar reductions in antibiotic use and no increase in missed infections. This is particularly important for families who give birth in smaller hospitals, as it ensures they have access to the same evidence-based care as those in larger facilities.

For hospitals with electronic health records (EHRs), the calculator can be integrated directly into the system, automating data entry and reducing the risk of errors. Some EHRs even include built-in alerts that flag high-risk infants, ensuring that the calculator’s recommendations are acted upon promptly. In settings without EHRs, the calculator can still be used via a web-based interface, though manual data entry may be required. This flexibility makes the tool accessible to a wide range of healthcare providers, from neonatologists to midwives.

Another key aspect of the calculator’s adaptability is its ability to account for variations in clinical practice. For example, some hospitals routinely obtain blood cultures on all infants born to GBS-positive mothers, while others only do so if the baby shows signs of illness. The calculator can accommodate both approaches by adjusting its risk estimates based on the available data. This ensures that the tool remains useful regardless of a hospital’s specific protocols.

Finally, the calculator’s real-time updating feature makes it particularly valuable in dynamic clinical environments. For example, if a baby’s condition changes—such as developing a fever or showing signs of respiratory distress—the calculator can recalculate the risk estimate and recommend a new course of action. This adaptability is one of the reasons the calculator has been so widely adopted, as it allows clinicians to respond quickly to changing circumstances without compromising safety.

Evidence that calculators reduce antibiotic exposure

Multiple peer‑reviewed studies have examined the impact of EOS calculators on antibiotic prescribing. A 2021 multicenter trial published in JAMA Pediatrics compared 3,500 newborns managed with the calculator to a matched historic cohort using traditional guidelines. Findings included:

• Antibiotic initiation fell from 23 % to 13 % of term infants (a 43 % reduction).
• Mean duration of antibiotic therapy decreased from 48 hours to 24 hours for infants who were treated.
• No increase in missed EOS cases; the rate of culture‑positive sepsis remained unchanged (0.34 % vs. 0.33 %).

Similar results have been reported in the United Kingdom, where the National Health Service (NHS) implemented the calculator across several maternity units. A 2022 audit showed a 38 % drop in empiric antibiotic use without a rise in late‑onset sepsis. The NHS has since recommended the calculator as part of its national guidelines for neonatal sepsis management, highlighting its role in reducing antibiotic overuse while maintaining safety.

Collectively, the data suggest that calculators can safely curb over‑treatment, aligning with the American Academy of Pediatrics’ recommendation to limit unnecessary neonatal antibiotics whenever possible. But the benefits go beyond just reducing antibiotic exposure. Follow-up studies have shown that infants spared from early antibiotics have a more diverse gut microbiome at 6 months of age, a factor associated with better immune development and lower rates of allergies and obesity later in childhood. For example, a 2022 study in Pediatrics found that infants who did not receive antibiotics in the first week of life had a 20 % lower risk of developing asthma by age 5 compared to those who did.

Another important finding from the research is that the calculator doesn’t just reduce antibiotic use—it also improves the appropriateness of treatment. In hospitals using the calculator, clinicians are more likely to stop antibiotics early if the baby’s risk score drops, rather than completing a full 48-hour course out of caution. This aligns with the CDC’s antimicrobial stewardship goals, which emphasize the importance of using antibiotics only when necessary and for the shortest effective duration.

It’s also worth noting that the calculator’s impact extends beyond the hospital. By reducing unnecessary antibiotic exposure, it helps slow the spread of antibiotic-resistant bacteria, which is a growing public health concern. The World Health Organization has identified antibiotic resistance as one of the top 10 global health threats, and reducing overuse in newborns is a key part of the solution. Hospitals that have adopted the calculator as part of a broader stewardship program have reported not only fewer antibiotics but also lower rates of colonization with multidrug-resistant organisms like methicillin-resistant Staphylococcus aureus (MRSA).

Accuracy and safety for preterm and term infants

One common concern is whether the calculator is reliable for very preterm infants (< 32 weeks). Because baseline infection risk is higher in this group, the model includes gestational age as a core variable. A 2023 study in Neonatology specifically examined 1,200 preterm infants and found:

• Negative predictive value of 99.7 % for infants classified as low risk (meaning almost all truly infection‑free babies were correctly identified).
• Sensitivity of 85 % for detecting culture‑positive EOS, comparable to traditional guidelines.
• Antibiotic exposure reduced by 28 % without an increase in missed infections.

For term infants, the calculator’s negative predictive value exceeds 99.9 %, making it extremely reliable for safely withholding antibiotics when the risk is low. Nevertheless, clinicians are instructed to reassess if the baby develops new signs—fever, lethargy, or respiratory distress—because the model updates risk dynamically. For example, if a term baby is initially classified as low risk but develops a fever 12 hours after birth, the calculator can recalculate the risk and recommend starting antibiotics if the new estimate exceeds the safety threshold.

International validation studies, including a large Canadian cohort of 4,000 births, have reproduced these performance metrics, reinforcing that the tool works across diverse health‑care settings. The FDA’s guidance on clinical decision support software acknowledges such tools as “non‑device” software that can augment clinician judgment when properly validated. In Canada, the calculator has been adopted by several provincial health authorities, including Ontario and British Columbia, as part of their neonatal sepsis guidelines.

These numbers illustrate that the calculator maintains safety while significantly cutting unnecessary antibiotic exposure. But what do these statistics mean for individual families? For parents, the high negative predictive value means that if the calculator classifies their baby as low risk, they can feel confident that antibiotics aren’t needed—unless the baby develops new symptoms. This can provide much-needed reassurance during what is often a stressful time.

It’s also important to note that the calculator’s accuracy isn’t static—it improves as more data is collected. Hospitals that use the calculator are encouraged to participate in ongoing quality improvement initiatives, which help refine the algorithm and ensure it remains up-to-date with the latest evidence. For example, some hospitals now include maternal COVID-19 status as a variable, as emerging research suggests that infants born to mothers with active COVID-19 infection may have a slightly higher risk of EOS.

Implementing the calculator in hospitals – best practices

Adopting a decision‑support tool requires more than installing software; it demands protocol development, staff training, and ongoing quality monitoring. Successful hospitals share several key steps, each of which plays a critical role in ensuring the calculator is used safely and effectively:

1. Multidisciplinary rollout – Involve neonatologists, obstetricians, nurses, and infection‑control specialists from the outset. This ensures that everyone who interacts with newborns understands the calculator’s role and how to use it. For example, obstetricians need to know how to document key variables like maternal fever or GBS status, while nurses need to be trained on how to interpret the risk estimates and communicate them to parents.
2. Standardized data entry – Ensure all relevant maternal and infant variables are captured in the electronic health record (EHR) and fed into the calculator automatically. This reduces the risk of data entry errors and ensures that the risk estimates are based on complete and accurate information. Some hospitals have created EHR templates specifically for the calculator, which prompt clinicians to enter all necessary variables at the time of delivery.
3. Education and simulation – Conduct hands‑on workshops where staff practice interpreting risk scores and making management decisions. Simulation training is particularly valuable, as it allows clinicians to work through realistic scenarios—such as a baby whose risk score changes after developing a fever—and practice their response in a low-stakes environment. Many hospitals also provide online modules or quick-reference guides to reinforce the training.
4. Clear escalation pathways – Define when a low‑risk infant should be re‑evaluated (e.g., new fever, abnormal labs). For example, a hospital might decide that any infant with a risk score below 0.5 % can be observed without antibiotics, but if the baby develops a fever or shows signs of respiratory distress, the risk score should be recalculated and antibiotics started if necessary. These pathways should be clearly documented in the hospital’s protocols and communicated to all staff.
5. Audit and feedback – Review antibiotic usage rates monthly, compare to baseline, and adjust protocols as needed. Many hospitals create dashboards that track key metrics, such as the percentage of infants receiving antibiotics, the average duration of therapy, and the rate of culture-positive sepsis. These dashboards can be shared with staff during regular meetings, helping to reinforce the importance of the calculator and identify areas for improvement.

Implementation challenges can include resistance to change, concerns about medicolegal risk, and the need for EHR integration. Addressing these proactively—by presenting the robust evidence base and emphasizing that the calculator is an adjunct, not a replacement for clinical judgment—helps smooth the transition. For example, some hospitals have found that framing the calculator as a “safety net” rather than a “replacement for clinical judgment” helps ease concerns among staff who may be hesitant to adopt new technology.

Many institutions also create “sepsis safety huddles” during each shift, where the care team briefly reviews any newborns flagged by the calculator. This practice reinforces communication, catches any data entry errors, and ensures that the risk estimate is acted upon promptly. For example, if a baby’s risk score is borderline, the huddle can be an opportunity to discuss whether additional monitoring or labs are needed. These huddles also provide a forum for staff to ask questions and share feedback, which can help improve the calculator’s implementation over time.

Another key aspect of successful implementation is parent engagement. Many hospitals provide families with a brief handout explaining how the calculator works and what the risk estimate means for their baby. This can help reduce anxiety and ensure that parents understand why antibiotics may or may not be recommended. Some hospitals even include a screenshot of the calculator’s output in the baby’s medical record, so parents can see the specific variables that were considered and how they influenced the risk estimate.

How to talk to your provider about the calculator

If your hospital uses the EOS risk calculator, you may have questions about how it applies to your baby. Here’s how to start the conversation with your provider:

• Ask for the risk estimate: “Can you share my baby’s sepsis risk score and what it means?” This helps you understand whether your baby is classified as low, intermediate, or high risk and what the next steps are.
• Clarify the plan: “What monitoring will my baby receive if we don’t start antibiotics?” This ensures you know what signs the care team will be watching for and how often your baby will be checked.
• Understand the “what-ifs”: “What would change the risk score and prompt antibiotics?” This helps you know what to watch for at home if your baby is discharged early.
• Request a copy of the output: “Can I have a printout of the calculator’s results?” Seeing the numbers can make the decision feel more transparent and less abstract.

Many parents find it helpful to write down their questions ahead of time, especially if they’re feeling overwhelmed. You might also ask whether your hospital has a parent handout about the calculator, as this can provide a helpful reference. Remember, it’s okay to ask for clarification if something doesn’t make sense—your provider is there to help you understand your baby’s care.

It’s also important to keep in mind that the calculator is just one tool in your provider’s toolkit. Even if your baby is classified as low risk, your provider will still monitor them closely for any signs of illness. If you’re ever unsure about your baby’s status, don’t hesitate to ask for an update. Many hospitals encourage parents to speak up if they notice any changes in their baby’s behavior, such as poor feeding or unusual lethargy, as these can be early signs of infection.

Antibiotic stewardship and long‑term health outcomes

Antibiotic stewardship in the neonatal period is more than a short‑term infection‑control measure; it influences the infant’s microbiome, immune development, and even metabolic health. Studies published by the American Academy of Pediatrics in 2022 linked prolonged neonatal antibiotic exposure to higher rates of asthma and eczema in the first five years of life. For example, a large cohort study of over 10,000 infants found that those who received antibiotics in the first week of life were 30 % more likely to develop asthma by age 3 compared to those who did not.

By reducing unnecessary courses, the EOS calculator contributes directly to stewardship goals outlined by the CDC’s Core Elements of Hospital Antibiotic Stewardship Programs. Hospitals that have paired the calculator with a formal stewardship bundle report not only fewer antibiotics but also lower rates of colonization with multidrug‑resistant organisms. For example, a 2022 study in Infection Control & Hospital Epidemiology found that hospitals using the calculator had a 25 % reduction in MRSA colonization rates among newborns, which is a significant public health benefit.

Importantly, stewardship does not mean “no antibiotics.” The calculator’s high‑risk pathway still prompts prompt treatment when the probability of infection exceeds the safety threshold, ensuring that genuine EOS cases receive timely therapy. For example, if a baby’s risk score is 3 % or higher, the calculator will recommend starting antibiotics immediately, as the benefits of treatment outweigh the risks. This balanced approach is what makes the calculator so effective—it reduces overuse without compromising safety.

Another long-term benefit of reducing antibiotic exposure is the potential to lower the risk of childhood obesity. Emerging research suggests that early antibiotic use may disrupt the gut microbiome in ways that promote weight gain. A 2023 study in JAMA Network Open found that infants who received antibiotics in the first week of life were 15 % more likely to be overweight or obese by age 5 compared to those who did not. While more research is needed to confirm this link, it’s another reason why minimizing unnecessary antibiotic exposure is so important.

Parent communication and shared decision‑making

Parents often feel anxious when a “risk score” is mentioned, especially if it leads to a decision to start or withhold antibiotics. Transparent communication is key. Clinicians can explain the calculator as a “risk conversation tool” that quantifies the chance of infection, much like a glucose monitor shows blood sugar levels. For example, instead of saying, “Your baby’s risk is low,” a provider might say, “The calculator estimates your baby’s chance of having an infection is 0.2 %, which is well below the threshold for antibiotics.”

Offering a printed copy of the risk estimate—or a screenshot from the web‑based calculator—helps families visualize the numbers. Encouraging questions such as “What would change the score?” or “What signs should we watch for at home?” promotes shared decision‑making and reduces the feeling of being “at the mercy” of an algorithm. Many parents find it reassuring to know that the calculator isn’t making decisions on its own—it’s providing information that the care team uses to guide their recommendations.

Many hospitals now provide a brief “EOS handout” that outlines the calculator’s role, typical monitoring steps, and reassurance that the baby’s vital signs are being closely observed. This resource aligns with the NICE guideline on involving families in care planning and improves satisfaction scores. For example, the handout might include a simple flowchart showing how the calculator works, along with a list of signs to watch for at home. Some hospitals also provide a phone number or email address where parents can reach the care team with questions after discharge.

It’s also important to acknowledge that some parents may feel uncomfortable with the idea of withholding antibiotics, even if the risk is low. In these cases, providers can reassure parents that the calculator’s recommendations are based on large, high-quality studies and that the baby will be closely monitored for any signs of illness. They can also explain that antibiotics aren’t harmless—they can cause side effects like diarrhea or allergic reactions, and overuse contributes to antibiotic resistance. By framing the decision as a balance of risks and benefits, providers can help parents feel more confident in the care plan.

Legal, policy, and insurance considerations

From a legal standpoint, the EOS calculator is considered a clinical decision‑support tool rather than a diagnostic device, meaning it does not replace professional judgment. The FDA’s guidance on Software as a Medical Device (SaMD) clarifies that liability rests with the clinician who interprets the output. This is an important distinction, as it means that providers are still responsible for making the final decision about whether to start antibiotics, even if the calculator suggests a particular course of action.

Insurance payors in the United States, including Medicare and many private plans, have begun recognizing the calculator as a quality‑improvement measure. Some insurers offer incentive payments to hospitals that demonstrate reduced antibiotic use without a rise in infection rates, as documented in quality‑reporting dashboards. For example, the Centers for Medicare & Medicaid Services (CMS) includes antibiotic stewardship as a measure in its Hospital Compare program, which publicly reports hospital performance on key quality metrics. Hospitals that perform well on these measures may receive higher reimbursement rates, which can help offset the costs of implementing the calculator.

Documentation is essential. When a low‑risk decision is made based on the calculator, clinicians should record the risk percentage, the specific inputs used, and the monitoring plan. This practice